Alteogen presents ADC subcutaneous injection research at ESMO

Alteogen has presented research findings at the European Society for Medical Oncology (ESMO) 2026 congress in Madrid regarding the conversion of Antibody-Drug Conjugates (ADCs) to subcutaneous (SC) injection formulations using its platform technology, ALT-B4.

Using its HER2-targeted ADC, ALT-P7, in animal studies, the company demonstrated that ALT-B4 promotes dose-dependent drug absorption while maintaining bioavailability similar to intravenous (IV) administration. The research indicated that subcutaneous delivery helps distribute the drug uniformly across skin tissue, reducing localized skin damage.

Crucially, the study showed that the subcutaneous method results in a lower peak blood concentration (Cmax) compared to IV administration. This characteristic may mitigate systemic toxicity, specifically showing potential to reduce side effects such as neutropenia and hepatotoxicity.

Alteogen previously entered a licensing agreement with Daiichi Sankyo to develop subcutaneous ADC formulations. The company's ALT-B4 technology has also been applied to Merck & Co.’s (MSD) Keytruda subcutaneous formulation, which received FDA approval last year.